MT Newswires
- Home
- IRON
IRON
Disc Medicine Inc.
as of 03-02-2026 3:51pm EST
$66.38
$0.20
-0.30%
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 3.0B | IPO Year: | 2020 |
| Target Price: | $99.54 | AVG Volume (30 days): | 943.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.01 | EPS Growth: | -51.77 |
| 52 Week Low/High: | $30.82 - $99.50 | Next Earning Date: | 05-29-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 215.03% |
| P/E Ratio: | -11.08 | Index: | N/A |
| Free Cash Flow: | -181326000.0 | FCF Growth: | N/A |
AI-Powered IRON Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.54%
71.54%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
Franchi Jean M.
Sell
Chief Financial Officer
IRON Feb 25, 2026
Avg Cost/Share
$69.06
Shares
353
Total Value
$24,377.09
Owned After
70,990
SEC Form 4
Quisel John D
Sell
Chief Executive Officer
IRON Feb 17, 2026
Avg Cost/Share
$62.86
Shares
13,264
Total Value
$833,775.04
Owned After
226,064
SEC Form 4
Stephenson Pamela
Sell
Chief Commercial Officer
IRON Feb 17, 2026
Avg Cost/Share
$62.86
Shares
5,531
Total Value
$347,678.66
Owned After
80,998
SEC Form 4
Khara Rahul
Sell
Chief Legal Officer
IRON Feb 17, 2026
Avg Cost/Share
$62.86
Shares
2,853
Total Value
$179,339.58
Owned After
52,173
SEC Form 4
Savage William Jacob
Sell
Chief Medical Officer
IRON Feb 17, 2026
Avg Cost/Share
$62.86
Shares
3,256
Total Value
$204,672.16
Owned After
92,589
SEC Form 4
Yu Jonathan Yen-Wen
Sell
Chief Operating Officer
IRON Feb 17, 2026
Avg Cost/Share
$62.86
Shares
3,231
Total Value
$203,100.66
Owned After
54,324
SEC Form 4
Khara Rahul
Sell
Chief Legal Officer
IRON Jan 20, 2026
Avg Cost/Share
$69.74
Shares
1,000
Total Value
$69,740.00
Owned After
52,173
SEC Form 4
Khara Rahul
Sell
Chief Legal Officer
IRON Jan 2, 2026
Avg Cost/Share
$78.52
Shares
6,500
Total Value
$511,471.76
Owned After
52,173
Bitterman Kevin
Sell
Director
IRON Dec 17, 2025
Avg Cost/Share
$91.47
Shares
754
Total Value
$68,968.38
Owned After
14,013
Bitterman Kevin
Sell
Director
IRON Dec 16, 2025
Avg Cost/Share
$91.24
Shares
68,923
Total Value
$6,288,534.52
Owned After
14,013
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Franchi Jean M. | IRON | Chief Financial Officer | Feb 25, 2026 | Sell | $69.06 | 353 | $24,377.09 | 70,990 | |
| Quisel John D | IRON | Chief Executive Officer | Feb 17, 2026 | Sell | $62.86 | 13,264 | $833,775.04 | 226,064 | |
| Stephenson Pamela | IRON | Chief Commercial Officer | Feb 17, 2026 | Sell | $62.86 | 5,531 | $347,678.66 | 80,998 | |
| Khara Rahul | IRON | Chief Legal Officer | Feb 17, 2026 | Sell | $62.86 | 2,853 | $179,339.58 | 52,173 | |
| Savage William Jacob | IRON | Chief Medical Officer | Feb 17, 2026 | Sell | $62.86 | 3,256 | $204,672.16 | 92,589 | |
| Yu Jonathan Yen-Wen | IRON | Chief Operating Officer | Feb 17, 2026 | Sell | $62.86 | 3,231 | $203,100.66 | 54,324 | |
| Khara Rahul | IRON | Chief Legal Officer | Jan 20, 2026 | Sell | $69.74 | 1,000 | $69,740.00 | 52,173 | |
| Khara Rahul | IRON | Chief Legal Officer | Jan 2, 2026 | Sell | $78.52 | 6,500 | $511,471.76 | 52,173 | |
| Bitterman Kevin | IRON | Director | Dec 17, 2025 | Sell | $91.47 | 754 | $68,968.38 | 14,013 | |
| Bitterman Kevin | IRON | Director | Dec 16, 2025 | Sell | $91.24 | 68,923 | $6,288,534.52 | 14,013 |
Latest Disc Medicine Inc. News
IRON Breaking Stock News: Dive into IRON Ticker-Specific Updates for Smart Investing
Motley Fool
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction
📊
AI Sentiment
Positive
7/10
Motley Fool
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
📈
AI Sentiment
Highly Positive
10/10
GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
7/10
Compare IRON vs Leading Stocks
See how IRON stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.